Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Saved in:
| Title: | Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. |
|---|---|
| Authors: | Blauvelt, Andrew1 (AUTHOR) ablauvelt@oregonmedicalresearch.com, Lomaga, Mark2 (AUTHOR), Burge, Russel3,4 (AUTHOR), Zhu, Baojin3 (AUTHOR), Shen, Wei3 (AUTHOR), Shrom, David3 (AUTHOR), Dossenbach, Martin5 (AUTHOR), Pinter, Andreas6 (AUTHOR) |
| Source: | Journal of Dermatological Treatment. Mar2020, Vol. 31 Issue 2, p141-146. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 09546634 |
|---|---|
| DOI: | 10.1080/09546634.2019.1587146 |
